Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 67 | 0.91 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 12484
Sealed predictions
- ARHGAP18 in dopamine neurons, braak+0.30 (p 0.430) → -0.41 (p 0.272)receipt 12490
Swarm cases
receipt 12490: ARHGAP18 in dopamine neurons, braak
- power
- full sample -0.09 (p 0.728, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.14 (p 0.567, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.20 (p 0.418, n 18). could be the mix.
- skeptic
- leave-one-out range -0.21 to +0.03, sign flips 2; without severely affected donors -0.09 (p 0.728, n 18). fragile.
- cell type
- strongest in microglia: +0.65 (p 0.0033, n 18) vs -0.09 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ARHGAP18 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ARHGAP18 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.28 p 0.328 (needs p < 1.8e-4)
Receipts
loading the receipts